High Prevalence of Common Sexually Transmitted Diseases in Patients with Urological Symptoms Attending the Public Hospital Network from the City of Bogotá, Colombia

Hernán Vargas*, John E Gutíerrez*, Estefania Rojas*, Dayanne Rodríguez*, Sandra L Gómez†, Patricia Arcea*, Carlos Pinto† and Carlos D Goli‡

1Laboratorio de Salud Pública, Dirección de Epidemiología, Análisis y Gestión de Políticas de Salud Colectiva, Subsecretaría de Salud Pública, Secretaría Distrital de Salud, Bogotá, Colombia
2Facultad de Ciencias Veterinarias UNLP, IGEVET-Instituto de Genética Veterinaria “Ing. Fernando Dulout” (UNLP-CONICET LA PLATA), La Plata, Buenos Aires, Argentina

Abstract

Sexually transmitted infections (STI) are a group of bacterial, viral, parasite and fungal diseases of high public health concern worldwide, affecting both men and women. The aim of the present study was to establish the prevalence of a set of STI causative microorganisms in urine samples from a sexually active population presenting urological symptoms and attending a public hospital network in Bogotá, Colombia. The presence of Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Ureaplasma urealyticum, Ureaplasma parvum, Trichomonas vaginalis, Mycoplasma hominis, HPV 6/11 and Herpes simplex virus types 1 and 2, was determined using a molecular approach. Overall, positivity for any of the studied STI was 60 and 10% for women and men, respectively. The presence of urinary symptoms was associated with the highest percentage (61.1 and 75% in women and men, respectively). These results provide insights into the movement and behavior of microorganisms causing STI in the sexually active population and their possible association with urinary problems.

Keywords: Sexually transmitted infections; Prevalence; Molecular approach

Introduction

Sexually transmitted infections (STI) are considered a public health problem that may cause disease symptoms in sexually active men and women [1]. STI involve several bacteria (Chlamydia trachomatis, Neisseria gonorrhoeae, Ureaplasma spp., Mycoplasma spp., Treponema pallidum and Haemophilus ducreyi), viruses (human Papillomavirus types 6 and 11 [HPV 6/11]), Herpes simplex virus types 1 and 2 [HSV-1/2], human immunodeficiency virus [HIV] and hepatitis B virus [HBV], parasites (Trichomonas vaginalis) and yeasts (Candida albicans), promoting globally distributed diseases with high morbidity and mortality [2].

According to the World Health Organization (WHO), 357 million new cases of Chlamydia, Neisseria gonorrhoeae, Treponema pallidum and Trichomonas vaginalis were reported in the past year, only in the US continent the region of the Americas [3]. This situation should urge national and international organizations to exert every effort to control STI-caused diseases by designing promotion and prevention programs for sexual and reproductive health improvement. However, the diagnostic systems used in district and national screening programs do not cover all the microorganisms associated with STI, and the efficacy of these identification systems relies not only on their sensitivity and specificity, on sample type and positive and negative predictive values, but also on the prevalence of these pathogens in the general population [4]. In this sense, molecular techniques provide higher sensitivity (90% to 95%) and specificity (95%) through non-invasive alternatives such as urine samples, allowing an easy estimation of the prevalence of pathogens in sexually active men and women [5]. Also, the analysis of urine with molecular approaches enables STI identification in certain pathologies where other microorganisms with similar clinical symptoms are responsible for disease development and are not properly treated, such as urinary tract infections (UTI), urethritis, cystitis and kidney stones [6]. The aim of the present study was to establish the prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae and other microorganisms causing STI, such as Mycoplasma hominis, Mycoplasma genitalium, Ureaplasma urealyticum, Ureaplasma parvum, Trichomonas vaginalis, HPV 6/11 and HSV 1/2, in urine samples from a sexually active population attending a public hospital network in Bogota, Colombia.

Materials and Methods

One hundred urine samples obtained from 60 women and 40 men between 18 and 65 years of age were collected in the period January–June 2015. All patients signed a voluntary informed consent and responded a brief questionnaire. Sexually inactive subjects, minor patients or patients under antibiotic treatment were excluded. The study protocol was approved by the Ethics Committee from the Secretary of Public Health, Bogota, Colombia.

Urine sample collection

The Cobas® PCR Urine Sample Kit (Roche Molecular Diagnostics, USA) was used to collect 20 to 50 ml urine for Chlamydia trachomatis and Neisseria gonorrhoeae DNA detection. Another 15 ml of urine were centrifuged at 2500 g for 10 min, and the pellet was processed for DNA detection. Another 15 ml of urine were centrifuged at 2500 g for 10 min, and the pellet was processed for DNA detection. Another 15 ml of urine were centrifuged at 2500 g for 10 min, and the pellet was processed for DNA detection. Another 15 ml of urine were centrifuged at 2500 g for 10 min, and the pellet was processed for DNA detection. Another 15 ml of urine were centrifuged at 2500 g for 10 min, and the pellet was processed for DNA detection. Another 15 ml of urine were centrifuged at 2500 g for 10 min, and the pellet was processed for DNA detection.

*Corresponding author: Hernán Vargas, Laboratorio de Salud Pública, Dirección de Epidemiología, Análisis y Gestión de Políticas de Salud Colectiva, Subsecretaría de Salud Pública, Secretaría Distrital de Salud, Bogotá, Colombia. Tel: 3849090-9481; E-mail: havargas@saludcapital.gov.co

Received June 20, 2018; Accepted July 15, 2018; Published July 18, 2018

Citation: Vargas H, Gutíerrez JE, Rojas E, Rodríguez D, Gómez SL, et al. (2018) High Prevalence of Common Sexually Transmitted Diseases in Patients with Urological Symptoms Attending the Public Hospital Network from the City of Bogotá, Colombia. J Med Microb Diagn 7: 278. doi:10.4172/2161-0703.10000278

Copyright: © 2018 Vargas H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
detection of *Mycoplasma hominis*, *Mycoplasma genitalium*, *Ureaplasma urealyticum*, *Ureaplasma parvum*, *Trichomonas vaginalis*, HPV 6/11 and HSV 1/2 DNA. Samples were stored at 8°C and -20°C, as appropriate, in the facilities of the Public Health Laboratory, Bogotá, Colombia, until processing for DNA analysis.

**Molecular detection**

The molecular identification of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* was performed using the Cobas® 4800 CT/NG Test (Roche), according to the manufacturer’s instructions [7]. Molecular testing of *Mycoplasma hominis*, *Mycoplasma genitalium*, *Ureaplasma urealyticum*, *Ureaplasma parvum*, *Trichomonas vaginalis*, HPV 6/11 and HSV-1/2 was performed using the commercial GenoFlow STD Array Test Kit (Diagcor, Hong Kong, China). This technique is based on PCR amplification and subsequent “continuous flow” hybridization, which allows the identification of nine pathogens in a single PCR reaction and one hybridization process [8].

**Statistical analysis**

Sample size was calculated with the number of positive urine cultures obtained at the Hospital “El Tunal ESE Bogota Level III” during 2014 and STI prevalence in the district of Bogotá [9]. Epi Info version 3.5.1 was used for data analysis, indicating that 100 samples were enough to reach 95% confidence and 5% total error. STI prevalence as well as all additional relationships of sociodemographic and clinical data were analyzed in a database developed in Microsoft Excel.

**Results**

Sixty percent (36/60) of women had at least one STI causative organism. Among them, the prevalence of *Ureaplasma spp.* was 94.0%, followed by *Mycoplasma hominis* (22.2%), *Chlamydia trachomatis* (14%) and *Trichomonas vaginalis* (2.8%). All female patients were negative for *Neisseria gonorrhoeae*, *Mycoplasma genitalium*, HPV 6/11 and HSV-1/2 (Figure 1). However, 30.6% of samples were positive for multiple infections, namely, *Ureaplasma spp.* and *Mycoplasma hominis* showed the highest prevalence (18.0%), followed by *Mycoplasma hominis* and *Chlamydia trachomatis* (13.0%). In men 10% (4/40) of the analyzed samples had at least one STI causative organism. Similarly, the prevalence of *Ureaplasma spp.* was 60.0%, followed by *Chlamydia trachomatis* and HPV 6/11 (20.0%).

Results of the relationship between STI prevalence in women and UTI episodes showed that 22/39 (61.1%) of women had the highest STI prevalence, being *Ureaplasma spp.* responsible for the highest number of STI cases (n=21) (Table 1). Considering the microscopic findings in the 60 female patients, 40 (66.7%) underwent urinalysis and 20 (33.3%) underwent urine culture. More than half (51.7%) of patients showing a cellularity ≥ 2 cells/field presented an STI, while patients with a cellularity ≥ 3 cells/field (27.5%) and >4 leukocytes/field (25.0%) were always STI-positive. Further, 75.0% of patients with ≥ 3 bacteria/field and patients with a positive urine culture were always positive for an STI.

Among men reporting urinary tract symptoms, 66% presented *Ureaplasma spp.* infection and 33% displayed *Chlamydia trachomatis* infection. Microscopic findings showed that 27/40 male patients underwent urinalysis and 13/40 underwent urine culture. Almost 7.4% of patients referred to urinalysis (≥ 2 cells/field) had an STI. Patients with ≥ 4 leukocytes/field were always positive for an STI, and 4% of

![Figure 1: Positivity of STI-causative micro-organisms according to sex. * HSV-1/2: Herpes simplex virus type 1 (HSV-1) and Herpes simplex virus type 2 (HSV-2). ** HPV: Low-risk human papillomavirus types 6 and 11.](image-url)
patients showing ≥ 2 bacteria/field showed an STI. Finally, 100% of men with ≥ 3 bacteria/field were positive for an STI. Among patients with a negative urine culture (10/13), 20% showed an STI (Table 2).

**Discussion**

Our results showed that 94% of women were positive for *Ureaplasma spp.*, 22.2% were positive for *Mycoplasma hominis* and 14.0% for *Chlamydia trachomatis*. According to Sánchez and coworkers, *Ureaplasma spp.* is the most common organism in infections associated with urogenital mycoplasma species, and it may associate with other biological agents [9]. Thus, this group of pathogens is quite important in sexual and reproductive health and should be evaluated in routine microbiology laboratories. In the case of *Chlamydia trachomatis* infections, our results agree with those recently published reporting 9.7% prevalence in patients with cervicovaginal symptoms, 12.2% prevalence in sexually active women from Brazil and, more recently, 15.79% prevalence using an immunofluorescence technique [10-12].

In general, chlamydial genital infections present non-specific signs and symptoms, although most infections are asymptomatic [11]. This is crucial due to the significant role played by *C. trachomatis* in the etiology of urethritis in adults and children and because of its association with urinary tract infections, causing important clinical pictures such as cervicitis, pelvic pain syndrome and vaginal discharge syndrome in sexually active women [12,13].

In this study, the prevalence of multiple infections in women was 30.6%, being *Mycoplasma hominis* and *Trichomonas vaginalis* always associated with *Ureaplasma spp.*. A report published by Sánchez and coworkers showed that 45.5% of positive cases were due to multiple infections, always associated with *Ureaplasma spp.* and *Mycoplasma hominis* [14]. Therefore, the fact that mycoplasma infections appear associated with other pathogens could be probably explained by the microflora present in vaginal mucosa, which can be exchanged with other microorganisms from mucous membranes and skin during sexual activity [15,16]. Among men, 60% of samples were positive for *Ureaplasma spp.*, 20% for *Chlamydia trachomatis* and 20% for HPV 6/11. According to Laspina and colleagues *Ureaplasma spp.* and *Chlamydia trachomatis* are the most common pathogens responsible for clinical situations in men, along with gonococcal urethritis and other genitourinary infections that, in some way, can be a source of infection for women [17-19].

Around sixty percent of STI positivity was associated with urinary symptoms. Such prevalence would be justified by the high number of microorganisms affecting the genitourinary system of women. Further, it could be explained because the female urethra is shorter and therefore promotes not only the interaction of both the normal flora of mucous and the surrounding skin, but also the spread of STI causative microorganisms. Similarly, the rate of UTI in women may increase with age and postmenopausal sexual activity due to pelvic prolapse, lack of estrogen and peri urethral normal flora colonization, allowing the concomitant growth of other microorganisms [20]. In another study, Sánchez and coworkers showed that urinary symptoms could present similarities with specific STI symptoms, such as cystitis, burning sensation when urinating, increased number of urination events and discomfort due to friction with the urethra [14]. These authors also related the presence of different UTI with organisms causing STI.

*Ureaplasma spp.* had the highest positivity in women who reported urinary symptoms (58.3%), followed by *Mycoplasma hominis* (19.4%). These results are comparable with those reported by Acosta and coworkers, who mentioned that 48% of cultures from patients with chronic urinary symptoms were *Ureaplasma spp.* positive [21]. Also, 7.9% of urine samples from patients showing chronic pyelonephritis obtained by suprapubic punction were positive for *Ureaplasma spp.* and *Mycoplasma hominis*. These microorganisms have also been isolated from patients with stones, because ureaplasma induces struvite phosphate and calcium crystallization in urine [22]. Thus, they should be differentiated as STI episodes in UTI-associated pathologies.

| Urinary symptom | Positive STI cases |
|-----------------|-------------------|
|                 | WOMEN | MEN |
|                 | n=36  | n=4 | % | % |
| Yes             | 22    | 3   | 61.1 | 75.0 |
| No              | 12    | 1   | 33.3 | 25.0 |
| Unknown         | 2     | 0   | 5.6  | 0   |

**Table 1:** Positive STI according to urinary symptoms.

| URINALYSIS | WOMEN | MEN |
|------------|-------|-----|
|            | (n=60) | (n=36) | % | (n=40) | Positive STI (n=4) | % |
| Cellularity ≤ 2 XC | 29 | 15 | 51.7 | 27 | 2 | 7.4 |
| Cellularity ≥ 3 XC | 11 | 11 | 100 | 0 | 0 | 0 |
| Total        | 40 | 26 | -- | 27 | 2 | -- |
| Leukocytes ≤ 3 XC | 30 | 16 | 53.3 | 26 | 1 | 3.8 |
| Leukocytes ≥ 4 XC | 10 | 10 | 100 | 1 | 1 | 100 |
| Total        | 40 | 26 | -- | 27 | 2 | -- |
| Bacteria ≤ 2+ | 36 | 23 | 63.9 | 26 | 1 | 3.8 |
| Bacteria ≥ 3+ | 4 | 3 | 75 | 1 | 1 | 100 |
| Total        | 40 | 26 | -- | 27 | 2 | -- |

**Table 2:** Positive STI associated with urinalysis and urine culture.

| Urine Culture | Positive | Negative | Total |
|---------------|----------|----------|-------|
| Positive      | 5        | 15       | 20    |
| Negative      | 5        | 5        | 10    |
| Total         | 20       | 20       | 40    |

XC: Observations per microscopic field. 2+, 3+: Bacteria crossover according to the microscopic field observed.
In the group of women who underwent urinalysis, 11 presented ≥ 3 STI-positive cells per field. This result is supported by Martinez et al., who described several mechanisms of response to infections produced by the host when reporting the pathophysiology of UTI, such as adhesion of bacteria to specific molecules on the cell surface of urothelial epithelium, or the drag of infected cells by urine flow, which could be responsible for the association of STI with cell observation [23]. This process would also be assisted by the production of secretory IgA, which magnifies the inflammation and cell desquamation process.

In men, STI positivity related to urinary symptoms was 75.0%, showing that symptoms such as dysuria and burning during urination are associated not only with UTI but also with a silent STI not clearly diagnosed [24]. The same as in women, Ureaplasma spp. had the highest percentage of positivity (50.0%). These data are directly related to the diagnosis of nongonococcal urethritis, which produces itching in the meatus, urethral discharge and dysuria, deviating from the appropriate clinical management for disease treatment [25]. However, another study considered that infections by Ureaplasma spp. depend directly on the bacterial load and the microbial genotype involved in episodes of asymptomatic or symptomatic nongonococcal urethritis [26]. In this sense, genotyping of ureaplasma could help differentiate commensal from pathogenic microflora in the male urethra.

Among male patients who underwent urinalysis, 2/27 showing ≤ 2 cells/field were STI-positive (7.4%). This drop-in positivity, compared from pathogenic microflora in the male urethra.

Conclusion

This is the first study performed in the city of Bogotá in symptomatic UTI patients determining positivity profiles of STI causative microorganisms that may trigger important public health clinical pictures, which are disregarded when designing promotion and prevention sexual and reproductive health programs.

Acknowledgement

The authors appreciate the collaboration of the Hospital “El Tunal E.S.E III Nivel” staff members for sample collection and contact with the participating patients, and the Public Health Laboratory of the Health District Secretary, Bogotá, Colombia. We also thank A.Di Maggio for manuscript correction.

References

1. World Health Organization (2005) Transmission infections and other reproductive tract infections.A guide to basic practice.  
2. Cao B, Wang S, Tian Z, Hu P, Feng L, et al. (2015) DNA microarray characterization of pathogens associated with sexually transmitted diseases. PloS one 10: e0133927.  
3. Ginindza TG, Stefan CD, Tsoka-Gwefweni JM, DiAmain X, Jolly PE, et al. (2017) Prevalence and risk factors associated with sexually transmitted infections (STIs) among women of reproductive age in Swaziland. Infect Agent Cancer 12: 29.  
4. Vázquez F, Otero L, Ordás J, Junquera ML, Varela JA (2004) Update on sexually transmitted infections: Epidemiology, diagnosis and treatment. Enferm Infecct Microbiol Clin 22: 392-411.  
5. Parra M, Palomares JC, Bernal S, Sivianes N, Pérez L, et al. (2011) Evaluation of the cobas 4800 CT/NG test for the detection of Chlamydia trachomatis. Enferm Infecct Microbiol Clin 29: 421-424.  
6. Mahony JB, Jiang D, Chong S, Luinstra K, Sellers J, et al. (1997) Detection of Chlamydia trachomatis, Neisseria gonorrhoeae, Ureaplasma urealyticum, and Mycoplasma genitalium in first-vioid urine specimens by multiplex polymerase chain reaction. Mol diag 2: 161-168.  
7. Rockett R, Goire N, Limnios A, Turra M, Higgens G, et al. (2010) Evaluation of the cobas 4800 CT/NG test for detecting Chlamydia trachomatis and Neisseria gonorrhoeae. Sex transm infect 86: 470-473.  
8. Chow K (2008) A membrane-based flow-through hybridization technology: A rapid and versatile tool for molecular diagnostics. Open Biotech J 2: 22-28.  
9. Orellana M, Gómez M, Sánchez MT, Fernández-Chacón T (2009) Diagnosis of urethritis in men. A 3-year review. Revista Española de Quimioterapia: Publicación oficial de la Sociedad Española de Quimioterapia 22: 83-87.  
10. Buhrer-Skinner M, Muller R, Buettner PG, Gordon R, Debattista J (2013) Reducing barriers to testing for Chlamydia trachomatis by mailed self-collected samples. Sex Health 10: 32-38.  
11. Araujo RS, Guimarães EM, Alves MF, Sakural E, Domingos LT, et al. (2006) Prevalence and risk factors for Chlamydia trachomatis infection in adolescent females and young women in central Brazil. Eur J Clin Microbiol Infect Dis 25: 397-400.  
12. Frej-Madjraz M, Teryks-Wołyńc D, Jama-Kmiecie A, Sarowska J, Choroszy-Król I (2015) Diagnosing Chlamydia trachomatis urinary tract infections: Preliminary report. Adv Clin Exp Med 24: 441-445.  
13. Ghosh M, Choudhuri S, Ray RG, Bhattacharya B, Bhattacharya S (2015) Association of genital Chlamydia trachomatis infection with female infertility study in a tertiary care hospital in Eastern India.Open Microbiol J 9: 110-106.  
14. Casas AS, Fernández OMR, Frómelet LDT, Hechavarria LMP (2013) Mycoplasma hominis and Ureaplasma urealyticum in women with urogenital infections. Revista Africano Médico de Camagüey 17: 309-321.  
15. Maeda S, Deguchi T, Ishiko H, Matsumoto T, Naito S, et al. (2004) Detection of Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma parvum (biovar 1) and Ureaplasma urealyticum (biovar 2) in patients with non-gonococcal urethritis using polymerase chain reaction-microtroller plate hybridization. Int J urol 11: 750-754.  
16. Giselle De Souza A, Aparecida Sgarione B, Rubia Andrea Faleiros De PC, Rosilene F, Siquera Vera L (2007) Mipocalma hominis and Ureaplasma spp. in genitourinary specimens and their association with symptoms of genital infection. Rev Bras Anál Clin 38: 295-308.  
17. Kweon OJ, Lim YK, Oh SM, Kim T-H, Choe H-S, et al. (2016) Prevalence and antimicrobial susceptibility of Mycoplasma hominis, Ureaplasma urealyticum and Mycoplasma parvum in individuals with or without symptoms of genitourinary infections. Lab Med Online 6: 79-87.  
18. Laspina F, Samudio M, Meyer M, Guillen E, Farinha N, et al. (2010) Etiological aspects of male infectious urethritis in patients attending laboratories of Asunción. Mem Inst Investig Cienc Salud 8: 41-48.  
19. Meller B, Herrmann B, Itsen H, Halvær-Kørensen L, From E, et al. (1990) Occurrence of Ureaplasma urealyticum and Mycoplasma hominis in non-gonococcal urethritis before and after treatment in a double-blind trial of ofloxacin versus erythromycin. Scand J Infect Dis Suppl 68: 31-34.  
20. Al-Badr A, Al-Shaikh G (2013) Recurrent urinary tract infections management in women: A review. Sultan Qaboos Univ Med J 13: 359-367.  
21. Acosta B, Codina M, Matas L, Meseguer E, Cerconado E, et al. (2011) Diagnóstico microbiológico de las infecciones por Mycoplasma spp. y Ureaplasma spp. Cerconado E y Gantón R Procedimientos en Microbiología Clínica España: Seimc 2: 1.  
22. Larsson PA, Cano M, Grenabo L, Brorson JE, Hedelin H, et al. (1989) Mycoplasma spp. and Ureaplasma urealyticum in women with female infertility, showing that symptoms such as dysuria and burning during urination could be responsible for the association of STI with cell observation [23]. This process would also be assisted by the production of secretory IgA, which magnifies the inflammation and cell desquamation process. In men, STI positivity related to urinary symptoms was 75.0%, showing that symptoms such as dysuria and burning during urination are associated not only with UTI but also with a silent STI not clearly diagnosed [24]. The same as in women, Ureaplasma spp. had the highest percentage of positivity (50.0%). These data are directly related to the diagnosis of nongonococcal urethritis, which produces itching in the meatus, urethral discharge and dysuria, deviating from the appropriate clinical management for disease treatment [25]. However, another study considered that infections by Ureaplasma spp. depend directly on the bacterial load and the microbial genotype involved in episodes of asymptomatic or symptomatic nongonococcal urethritis [26]. In this sense, genotyping of ureaplasma could help differentiate commensal from pathogenic microflora in the male urethra.
25. Hernández JAS, Tapia JAR, Martínez SAC, Mendoza NT, Valderrábano FM (2003) Genitourinary and mycoplasma disorders. Lat Am J Clin Pathol Lab Med 50: 71-76.

26. Wetmore CM, Manhart LE, Lowens MS, Golden MR, Jensen NL, et al. (2011) Ureaplasma urealyticum is associated with Nongonococcal Urethritis among men with fewer lifetime sexual partners: A case-control study. J Infect Dis 204: 1274-1282.

27. Miranda AE, Szwarzwald CL, Peres RL, Page-Shafer K (2004) Prevalence and risk behaviors for chlamydial infection in a population-based study of female adolescents in Brazil. Sex Transm Dis 31: 542-546.